EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia

Haydar Frangoul iD, Rabi Hanna iD, Mark C Walters iD, Roy L Kao, Clinton Carroll, Meghann McManus, Kai-Hsin Chang, Michael C Jaskolka, Keunpyo Kim, Qifeng Yu, Nnenna Badamosi, Baisong Mei und 3 weitere

New England Journal of Medicine · 02.04.2026 · 394 (13) · 1292-1301

DOI: 10.1056/nejmoa2501277 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.04.2026. Verfasst von Haydar Frangoul und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville. Hauptthemen laut MEDLINE: beta-Thalassemia, CRISPR-Cas Systems, Fetal Hemoglobin, gamma-Globins. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Editas Medicine, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaCRISPR-Cas SystemsFetal Hemoglobingamma-GlobinsGenetic TherapyHematopoietic Stem Cell TransplantationErythrocyte TransfusionAdolescentAdultFemaleHumansMaleYoung AdultGene EditingNeutrophilsPromoter Regions, GeneticRepressor ProteinsBusulfanMyeloablative AgonistsTransplantation ConditioningTreatment Outcome

Substanzen

BCL11A protein, humanFetal Hemoglobingamma-GlobinsRepressor ProteinsBusulfanMyeloablative Agonists

Autor:innen und Institutionen

  • Sarah Cannon Research Institute, Nashville.
  • TriStar Centennial Children's Hospital, Nashville.
  • Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland.
  • School of Medicine, University of California, San Francisco, San Francisco.
  • Benioff Children's Hospital, Oakland, CA.
  • Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis.

ORCID-Profile: Haydar Frangoul, Rabi Hanna, Mark C Walters, Alexis Thompson

Förderung

  • Editas Medicine, Inc.

Zitieren

APA

Frangoul, H., Hanna, R., Walters, M. C., Kao, R. L., Carroll, C., McManus, M., Chang, K. H., Jaskolka, M. C., Kim, K., Yu, Q., Badamosi, N., Mei, B., Afonja, O., Thompson, A., & EdiThal Investigators (2026). CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia. New England Journal of Medicine, 394(13), 1292-1301. https://doi.org/10.1056/nejmoa2501277

Vancouver

Frangoul H, Hanna R, Walters MC, Kao RL, Carroll C, McManus M, et al. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia. New England Journal of Medicine. 2026;394(13):1292-1301. doi:10.1056/nejmoa2501277

BibTeX
@article{Frangoul2026,
  author = {Frangoul, Haydar and Hanna, Rabi and Walters, Mark C and Kao, Roy L and Carroll, Clinton and McManus, Meghann and Chang, Kai-Hsin and Jaskolka, Michael C and Kim, Keunpyo and Yu, Qifeng and Badamosi, Nnenna and Mei, Baisong and Afonja, Olubunmi and Thompson, Alexis and EdiThal Investigators, EdiThal Investigators},
  title = {CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {13},
  pages = {1292--1301},
  doi = {10.1056/nejmoa2501277}
}
Kostenlos starten →